IL324425A - Modified liposome for drug delivery, use of liposome for drug delivery, especially with anticancer activity, and methods of loading liposome with drugs, especially with anticancer activity - Google Patents

Modified liposome for drug delivery, use of liposome for drug delivery, especially with anticancer activity, and methods of loading liposome with drugs, especially with anticancer activity

Info

Publication number
IL324425A
IL324425A IL324425A IL32442525A IL324425A IL 324425 A IL324425 A IL 324425A IL 324425 A IL324425 A IL 324425A IL 32442525 A IL32442525 A IL 32442525A IL 324425 A IL324425 A IL 324425A
Authority
IL
Israel
Prior art keywords
liposomes
solution
liposome
drug
amount
Prior art date
Application number
IL324425A
Other languages
English (en)
Hebrew (he)
Inventor
Olga Swiech
Agata Krzak
Joanna Pietras
Weronika Piotrowska
Anna Boguszewska-Czubara
Mateusz Psurski
Joanna Wietrzyk
Ewa Oliszewska
Joanna Jarosz
Wojciech Smoro?
Renata Bilewicz
Original Assignee
Bs Biotechna Spo?Ka Akcyjna
Olga Swiech
Agata Krzak
Joanna Pietras
Weronika Piotrowska
Boguszewska Czubara Anna
Mateusz Psurski
Joanna Wietrzyk
Ewa Oliszewska
Joanna Jarosz
Wojciech Smoro?
Renata Bilewicz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bs Biotechna Spo?Ka Akcyjna, Olga Swiech, Agata Krzak, Joanna Pietras, Weronika Piotrowska, Boguszewska Czubara Anna, Mateusz Psurski, Joanna Wietrzyk, Ewa Oliszewska, Joanna Jarosz, Wojciech Smoro?, Renata Bilewicz filed Critical Bs Biotechna Spo?Ka Akcyjna
Publication of IL324425A publication Critical patent/IL324425A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
IL324425A 2023-05-03 2024-05-03 Modified liposome for drug delivery, use of liposome for drug delivery, especially with anticancer activity, and methods of loading liposome with drugs, especially with anticancer activity IL324425A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL444722A PL249575B1 (pl) 2023-05-03 2023-05-03 Modyfikowany liposom do przenoszenia leków, zwłaszcza o działaniu antynowotworowym
PCT/PL2024/000024 WO2024228633A1 (en) 2023-05-03 2024-05-03 Modified liposome for drug delivery, use of liposome for drug delivery, especially with anti-cancer activity, and ways to load liposome with drugs, especially with anti-cancer activity

Publications (1)

Publication Number Publication Date
IL324425A true IL324425A (en) 2026-01-01

Family

ID=91898578

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324425A IL324425A (en) 2023-05-03 2024-05-03 Modified liposome for drug delivery, use of liposome for drug delivery, especially with anticancer activity, and methods of loading liposome with drugs, especially with anticancer activity

Country Status (5)

Country Link
EP (1) EP4704811A1 (pl)
CN (1) CN121443273A (pl)
IL (1) IL324425A (pl)
PL (1) PL249575B1 (pl)
WO (1) WO2024228633A1 (pl)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2013086526A1 (en) * 2011-12-09 2013-06-13 The Regents Of The University Of California Liposomal drug encapsulation
CN105451720A (zh) * 2013-03-13 2016-03-30 马林克罗特有限公司 用于癌症疗法的脂质体奥沙利铂组合物
US20180369336A1 (en) * 2015-12-03 2018-12-27 Boston Medical Center Corporation B cell-based cancer immunotherapy
EP3530266A1 (en) * 2018-02-27 2019-08-28 LipoCoat B.V. A lipid-based coating composition, and an object having a lipid-based coating
PL249473B1 (pl) * 2021-08-14 2026-04-27 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie jako nośnika leku oraz w terapii genowej i sposób ładowania liposomu emetyną

Also Published As

Publication number Publication date
PL444722A1 (pl) 2024-11-04
CN121443273A (zh) 2026-01-30
PL249575B1 (pl) 2026-05-11
EP4704811A1 (en) 2026-03-11
WO2024228633A1 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
Liu et al. Recent advances on the development of pharmacotherapeutic agents on the basis of human serum albumin
Han et al. Efficient delivery of antitumor drug to the nuclei of tumor cells by amphiphilic biodegradable poly (L‐aspartic acid‐co‐lactic acid)/DPPE co‐polymer nanoparticles
Wang et al. Facile encapsulation of hydroxycamptothecin nanocrystals into zein-based nanocomplexes for active targeting in drug delivery and cell imaging
Li et al. Aptamer-conjugated chitosan-anchored liposomal complexes for targeted delivery of erlotinib to EGFR-mutated lung cancer cells
Ganta et al. Development of EGFR-Targeted Nanoemulsion for Imaging and Novel Platinum Therapy of Ovarian Cancer: Ganta et al.
RU2494729C2 (ru) Липосомальный фармацевтический препарат и способ его изготовления
Wu et al. All-stage targeted therapy for glioblastoma based on lipid membrane coated cabazitaxel nanocrystals
Zhu et al. Biomimetic nanoparticles to enhance the reverse cholesterol transport for selectively inhibiting development into foam cell in atherosclerosis
Goli et al. Preparation and evaluation of gemcitabin and cisplatin-entrapped Folate-PEGylated liposomes as targeting co-drug delivery system in cancer therapy
CN113975244B (zh) 一种仿生磁靶向阳离子脂质体及其制备方法和应用
US11607385B2 (en) Liposomes comprising sphingomyelin
Oltolina et al. Monoclonal antibody-targeted fluorescein-5-isothiocyanate-labeled biomimetic nanoapatites: A promising fluorescent probe for imaging applications
Kim et al. Nanoparticle platform comprising lipid-tailed pH-sensitive carbon dots with minimal drug loss
Mahmoodi et al. Formulation and therapeutic efficacy of PEG-liposomes of sorafenib for the production of NL-PEG-SOR FUM and NL-PEG-SOR TOS: NO Mahmoodi et al.
Tanzadehpanah et al. AS1411 aptamer improves therapeutic efficacy of PEGylated nanoliposomes loaded with gefitinib in the mice bearing CT26 colon carcinoma
US8865129B2 (en) Lanthanoid complex capsule and particle contrast agents, methods of making and using thereof
CN114917357A (zh) 转铁蛋白导向的装载plk1抑制剂的聚合物囊泡及其制备方法与应用
Saraf et al. pH-sensitive liposomes bearing a chemotherapeutic agent and a natural apoptosis modulator for effective intracellular delivery to the solid tumor
EP2896401B1 (en) Targeted drug delivery system for poorly soluble drug
Xu et al. The design and synthesis of redox-responsive oridonin polymeric prodrug micelle formulation for effective gastric cancer therapy
Duan et al. Highly water-soluble methotrexate-polyethyleneglycol-rhodamine prodrug micelle for high tumor inhibition activity
Qin et al. Synthetic genomic nanomedicine with triple-responsiveness for systemic anti-tumor therapy
EP4704811A1 (en) Modified liposome for drug delivery, use of liposome for drug delivery, especially with anti-cancer activity, and ways to load liposome with drugs, especially with anti-cancer activity
Yang et al. A pH-responsive prodrug biomimetic nanoplatform based on cis-aconitic anhydride-modified methotrexate for targeting therapy of oral squamous cell carcinoma
Wang et al. Fluorous-tagged bortezomib supramolecular nanomedicine for cancer therapy